YahooAugust 24, 2026 at 11:27 AM NY11 days ago

Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?

SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo

Companies in This Story